{"disease":{"id":"hepatocellular-carcinoma-recurrent","name":"hepatocellular carcinoma recurrent"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06233708","title":"Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant","phase":"","overall_status":"COMPLETED","enrollment_count":2092,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT04392700","title":"A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":706,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01015833","title":"Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":356,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02072356","title":"Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05444478","title":"Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":274,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07118202","title":"TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Barbara Ann Karmanos Cancer Institute","has_results":false},{"nct_id":"NCT04425226","title":"Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant","phase":"NA","overall_status":"UNKNOWN","enrollment_count":192,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03313648","title":"A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Southwest Hospital, China","has_results":false},{"nct_id":"NCT07489768","title":"GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":162,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05277675","title":"Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Southwest Hospital, China","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02867592","title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":109,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06609876","title":"Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04800497","title":"The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC","phase":"","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT02595866","title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03257761","title":"Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06254248","title":"Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02423343","title":"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT01900002","title":"Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02143401","title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06968195","title":"Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":24,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT05497453","title":"A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Omega Therapeutics","has_results":false},{"nct_id":"NCT04204850","title":"Cabozantinib to Treat Recurrent Liver Cancer Post Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05355155","title":"Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03563170","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT05327738","title":"Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}